Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Invite your friends, family, colleagues or clients to an exceptional black-tie event in the heart of London. Every ticket, every bid, every moment helps us move closer to a cure.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Join the type 1 diabetes community and come together, raising awareness and vital funds for T1D.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Her Majesty The Queen tours laboratory aiming to stop type 1 diabetes in its tracks
We have today welcomed our President, Her Majesty The Queen, to University College London (UCL) Institute of Immunity and Transplantation. It is here that Professor Lucy Walker, is working on research that aims to stop the immune attack responsible for type 1 diabetes and other autoimmune conditions.
Professor Walker’s research is funded by the Connect Immune Research Partnership, which was established by JDRF and other autoimmune charities (Versus Arthritis, MS Society and the British Society of Immunology) in 2018. This ground-breaking partnership brings together researchers with expertise in different autoimmune conditions to accelerate research and develop more sophisticated treatments and cures for the millions of people living with autoimmune conditions.
Her Majesty was welcomed to the Institute, which is based within the Pears Building at the Royal Free campus, by Dr Michael Spence, UCL President & Provost and Professor David Lomas, UCL Vice Provost (Health) before being warmly greeted by our Chief Executive Karen Addington and Professor Lucy Walker.
Professor Walker conducted a tour of her state-of-the art laboratories where Her Majesty learnt how immune cells from people with type 1 diabetes are studied in great depth. She went on to meet other members of Lucy’s team.
Her Majesty then joined a reception where she met our supporters including The Rt. Hon Theresa May MP, Derrick Evans MBE (Mr Motivator), Sheku Kanneh-Mason MBE, and Nina Wadia OBE who spoke about their first-hand experience of living with type 1 diabetes and their hopes for the future of research.
Karen Addington said: “We are delighted to welcome The Queen to Professor Lucy Walker’s lab and showcase the innovative work being carried out thanks to our Connect Immune Research Partnership. We are incredibly grateful for Her Majesty The Queen’s support since June 2012 as our President and for helping us raise awareness about the importance of research in advancing our understanding of type 1 diabetes, bringing us closer to a cure.”
Lucy Walker says: “It’s a huge honour to welcome Her Majesty to the UCL Institute of Immunity and Transplantation and showcase the research we do here in pursuit of a cure for type 1 diabetes. This visit highlights the critical importance of research in making discoveries that can lead to new treatments. It’s an incredibly exciting time in immunology where we are seeing real progress towards our goal of turning off unwanted immune responses. The support of funders such as JDRF is essential for these discoveries to be translated to life-changing therapies and I’m delighted that The Queen has honoured us with this visit.”
We’re pleased to announce that we are launching a new initiative to raise awareness of the importance of early detection in type 1 diabetes (T1D), with support from Sanofi.
In a landmark moment, the MHRA has licensed the use of teplizumab in the UK, the first-ever disease-modifying therapy for T1D.
In the study, nearly two thirds of young people diagnosed with type 1 diabetes (T1D) did not have the typical identifiers of the condition.
A recent study has shown that a treatment currently used for type 2 diabetes could be used to help prevent kidney damage in young adults with type 1.
